Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul;99(7):1392-1395.
doi: 10.1002/ajh.27303. Epub 2024 Mar 28.

A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia

Affiliations
Free article
Clinical Trial

A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia

Shi Yan et al. Am J Hematol. 2024 Jul.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386‐2393.
    1. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829‐2835.
    1. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.
    1. Yu T, Wang L, Ni X, Hou Y, Liu X, Hou M. Orelabrutinib, a selective Bruton's tyrosine kinase (BTK) inhibitor in the treatment of primary immune thrombocytopenia (ITP). Blood. 2021;138(Supplement 1):3172.
    1. Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an Oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022;386(15):1421‐1431.

Associated data

LinkOut - more resources